# Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)

> **NCT02071199** · PHASE1 · COMPLETED · sponsor: **Noveome Biotherapeutics, formerly Stemnion** · enrollment: 54 (actual)

## Conditions studied

- Gingivitis

## Interventions

- **DRUG:** 1X ACCS (Amnion-derived Cellular Cytokine Solution)
- **DRUG:** Normal saline
- **DRUG:** 0.3X ACCS

## Key facts

- **NCT ID:** NCT02071199
- **Lead sponsor:** Noveome Biotherapeutics, formerly Stemnion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-10
- **Final completion:** 2015-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2016-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02071199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02071199, "Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02071199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*